LivaNova (LIVN) Q4 2024 earnings summary

Executive summary

• Achieved 11% organic revenue growth in 2024, marking a second consecutive year of double-digit organic growth, led by strong Cardiopulmonary and high single-digit Neuromodulation growth.

• Adjusted operating income grew 41% year-over-year, with margin improvement of over 400bps and significant cash generation.

• Significant innovation milestones reached in obstructive sleep apnea (OSA), difficult-to-treat depression (DTD), and epilepsy (CORE VNS study), with pivotal clinical publications and OSPREY study meeting primary endpoints.

• Strengthened talent and culture, with 30% of director-level and above positions filled by new hires or promotions, and appointment of a new Chief Human Resources Officer in January 2025.

Financial highlights

• Full-year 2024 revenue reached $1.25B, up 9.3% constant-currency and 10.7% organic; Q4 revenue was $321.8M, up 6.8% organic year-over-year.

• Adjusted operating income grew 41% to $239.2M; adjusted diluted EPS was $3.38 for 2024 and $0.81 for Q4.

• Adjusted free cash flow for 2024 was $163M, up 70% from prior year.

• Adjusted gross margin in 2024 was 70.2%; Q4 adjusted gross margin was 69.3%.

• Cash balance at year-end 2024 was $429M; total debt $628M.

Outlook and guidance

• 2025 organic revenue growth guided at 6%-7%; constant currency growth 5%-6%, with FX headwind of 1.5–2.0%.

• Adjusted diluted EPS for 2025 expected in the range of $3.65-$3.75, representing 9% growth at midpoint.

• Adjusted free cash flow expected between $135M-$155M, with $90M in capital spending planned.

• Cardiopulmonary revenue expected to grow 7%-8%; epilepsy/neuromodulation revenue to grow 4%-5% globally in 2025.

• R&D as a percent of revenue expected to decrease over time as clinical spend winds down.